Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Antonella Castagna

Showing results (121-130 of 467) with videos related to

Pageof 47
Sort By:
Medicine|June 4, 2016
Estimated Glomerular Filtration Rate Trajectories in HIV-Infected Subjects Treated With Different Ritonavir-Boosted Protease Inhibitors and Tenofovir Disoproxil Fumarate or AbacavirNicola Gianotti, Laura Galli, Andrea Poli, et al.
Drug Design, Development and Therapy|April 15, 2024
Outcome of Darunavir-Cobicistat-Based Regimens in HIV-Infected People Who Have Experienced Virological FailureFrancesca Alberton, Laura Galli, Riccardo Lolatto, et al.
The Journal of Antimicrobial Chemotherapy|September 7, 2005
Higher plasma lopinavir concentrations are associated with a moderate rise in cholestasis markers in HIV-infected patientsElena Seminari, Gianluca Gentilini, Laura Galli, et al.
The New Microbiologica|March 3, 2018
Potential associations between atazanavir exposure and clinical outcome: a pharmacokinetic sub-study from the MODAt randomized trialElisa Colella, Dario Cattaneo, Laura Galli, et al.
The Journal of Antimicrobial Chemotherapy|October 28, 2017
Long-term efficacy of dolutegravir in treatment-experienced subjects failing therapy with HIV-1 integrase strand inhibitor-resistant virusAntonella Castagna, Micol Ferrara, Laura Galli, et al.
Plos One|February 3, 2022
Risk of HIV viral rebound in HIV infected patients on direct acting antivirals (DAAs) treatment for HCVGiulia Morsica, Laura Galli, Emanuela Messina, et al.
Plos One|March 15, 2022
Association between low levels of HIV-1 DNA and HLA class I molecules in chronic HIV-1 infectionCamilla Muccini, Monica Guffanti, Vincenzo Spagnuolo, et al.
Viruses|May 25, 2024
Monkeypox Virus Neutralizing Antibodies at Six Months from Mpox Infection: Virologic Factors Associated with Poor Immunologic ResponseAngelo Roberto Raccagni, Alessandro Mancon, Sara Diotallevi, et al.
AIDS (London, England)|December 20, 2003
Pharmacokinetics of amprenavir given once or twice a day when combined with atazanavir in heavily pre-treated HIV-positive patientsMonica Guffanti, Cleta Raffaella De Pascalis, E Seminari, et al.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|January 9, 2010
Viro-immunological dynamics in HIV-1-infected subjects receiving once-a-week emtricitabine to delay treatment change after failure: a pilot randomised trialAlessandro Soria, Anna Danise, Laura Galli, et al.
Pageof 47

Showing results (121-130 of 467) with videos related to

Sort By:
Pageof 47
Medicine|June 4, 2016
Estimated Glomerular Filtration Rate Trajectories in HIV-Infected Subjects Treated With Different Ritonavir-Boosted Protease Inhibitors and Tenofovir Disoproxil Fumarate or AbacavirNicola Gianotti, Laura Galli, Andrea Poli, et al.
Drug Design, Development and Therapy|April 15, 2024
Outcome of Darunavir-Cobicistat-Based Regimens in HIV-Infected People Who Have Experienced Virological FailureFrancesca Alberton, Laura Galli, Riccardo Lolatto, et al.
The Journal of Antimicrobial Chemotherapy|September 7, 2005
Higher plasma lopinavir concentrations are associated with a moderate rise in cholestasis markers in HIV-infected patientsElena Seminari, Gianluca Gentilini, Laura Galli, et al.
The New Microbiologica|March 3, 2018
Potential associations between atazanavir exposure and clinical outcome: a pharmacokinetic sub-study from the MODAt randomized trialElisa Colella, Dario Cattaneo, Laura Galli, et al.
The Journal of Antimicrobial Chemotherapy|October 28, 2017
Long-term efficacy of dolutegravir in treatment-experienced subjects failing therapy with HIV-1 integrase strand inhibitor-resistant virusAntonella Castagna, Micol Ferrara, Laura Galli, et al.
Plos One|February 3, 2022
Risk of HIV viral rebound in HIV infected patients on direct acting antivirals (DAAs) treatment for HCVGiulia Morsica, Laura Galli, Emanuela Messina, et al.
Plos One|March 15, 2022
Association between low levels of HIV-1 DNA and HLA class I molecules in chronic HIV-1 infectionCamilla Muccini, Monica Guffanti, Vincenzo Spagnuolo, et al.
Viruses|May 25, 2024
Monkeypox Virus Neutralizing Antibodies at Six Months from Mpox Infection: Virologic Factors Associated with Poor Immunologic ResponseAngelo Roberto Raccagni, Alessandro Mancon, Sara Diotallevi, et al.
AIDS (London, England)|December 20, 2003
Pharmacokinetics of amprenavir given once or twice a day when combined with atazanavir in heavily pre-treated HIV-positive patientsMonica Guffanti, Cleta Raffaella De Pascalis, E Seminari, et al.
Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology|January 9, 2010
Viro-immunological dynamics in HIV-1-infected subjects receiving once-a-week emtricitabine to delay treatment change after failure: a pilot randomised trialAlessandro Soria, Anna Danise, Laura Galli, et al.
Pageof 47